Modern antihypertensive therapy: a report from the 22nd annual meeting of the American Society of Hypertension.
Rabasseda
X
X
Prous Science Medical Information Department.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D019440:Anti-Obesity Agents / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D019405:Cytochrome P-450 CYP11B2 / Q000037:antagonists & inhibitors; D004032:Diet; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D020249:Hormone Replacement Therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006973:Hypertension / Q000628:therapy*; D048288:Imidazolines / Q000819:agonists; D045162:Thiazolidinediones / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use; D000092502:Renin Inhibitors
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D019440:Anti-Obesity Agents; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D019405:Cytochrome P-450 CYP11B2; D004232:Diuretics; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D048288:Imidazolines; D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000092502:Renin Inhibitors